Cargando…

Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing

OBJECTIVE: To investigate the clinicopathological characteristics and prognostic factors of early-stage breast cancer patients with indications for breast cancer susceptibility genes 1/2 (BRCA1/2) genetic testing in China. METHODS: Based on the indication criteria for BRCA genetic testing specified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Hongyu, Xin, Ling, Liu, Qian, Zhang, Hong, Zhang, Shuang, Ye, Jingming, Cheng, Yuanjia, Li, Ting, Liu, Yinhua, Xu, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219101/ https://www.ncbi.nlm.nih.gov/pubmed/32410794 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.04

Ejemplares similares

A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer
por: Ye, Jingming, et al.
Publicado: (2017)

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
por: Xin, Ling, et al.
Publicado: (2022)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

Corrigendum to Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing
Publicado: (2020)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
por: Li, Jiayi, et al.
Publicado: (2022)

Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period
por: Ding, Mao, et al.
Publicado: (2023)

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
por: Xu, Ling, et al.
Publicado: (2017)

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)
por: Cheng, Yuanjia, et al.
Publicado: (2022)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

A Clinical–Radiomics Model for Predicting Axillary Pathologic Complete Response in Breast Cancer With Axillary Lymph Node Metastases
por: Gan, Liangyu, et al.
Publicado: (2021)

Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading
por: Zhang, Shuang, et al.
Publicado: (2020)

Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial
por: Xiang, Hong-Yu, et al.
Publicado: (2019)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient
por: Zhang, Zhuo, et al.
Publicado: (2021)

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteria
por: Duffy, J, et al.
Publicado: (2012)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer
por: Li, Ling, et al.
Publicado: (2021)

Malaysian nurses’ knowledge and attitudes regarding BRCA genetic testing
por: Liu, Kien Ting, et al.
Publicado: (2021)

Correction: Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
por: Vasigh, Mahtab, et al.
Publicado: (2022)

Mutational analysis of BRCA1 and BRCA2 in northwest Chinese breast cancer patients
por: Wang, Ting, et al.
Publicado: (2019)

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
por: Bang, Yoon Ju, et al.
Publicado: (2022)

Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients
por: Kim, Eun-Kyu, et al.
Publicado: (2020)

Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?
por: Weber, BL
Publicado: (2000)

Validation of CPS+EG, Neo‐Bioscore, and modified Neo‐Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
por: Xu, Ling, et al.
Publicado: (2018)

Comparison of the clinicopathological features and prognoses of patients with schistosomal and nonschistosomal colorectal cancer
por: Wang, Zijian, et al.
Publicado: (2020)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis
por: Li, Haoran, et al.
Publicado: (2019)

Changing Patterns in Clinicopathological Characteristics of Breast Cancer and Prevalence of BRCA Mutations: Analysis in a Rural Area of Southern China
por: Wang, Qiuming, et al.
Publicado: (2021)

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
por: Zhou, Zhijun, et al.
Publicado: (2021)

Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

BRCA1 testing
por: Górski, Bohdan, et al.
Publicado: (2008)

Quantitative Analysis of BRCA1 and BRCA2 mRNA Expression in Sporadic Breast Carcinomas and Its Relationship with Clinicopathological Characteristics
por: Egawa, Chiyomi, et al.
Publicado: (2001)

Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis
por: Li, Zhiqiang, et al.
Publicado: (2022)

Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population
por: Wong, Edward S. Y., et al.
Publicado: (2015)

Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study
por: Mella, Sara, et al.
Publicado: (2017)

In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing
por: Poon, Kok-Siong
Publicado: (2021)

Patients’ Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing
por: Wright, Sarah, et al.
Publicado: (2018)

Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics
por: Huang, Xianghua, et al.
Publicado: (2021)

Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan
por: Tsai, Hsien-Ying, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cm1ub70plecqvsr8mhrupkapln